MedPath

A randomised,double-blind, placebo-controlled, multi-national, multi-centre, Phase III extension study to assess the long term efficacy, safety and carry-over effect of one of sublingual immunotherapy SLIT administered asllegen-based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis

Conditions
allergic rhinoconjunctivitis due to grass pollen
Registration Number
EUCTR2005-002501-23-IT
Lead Sponsor
STALLERGENES
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
Ā© Copyright 2025. All Rights Reserved by MedPath